search
Back to results

Paracetamol and Patent Ductus Arteriosus (PDA)

Primary Purpose

Patent Ductus Arteriosus

Status
Unknown status
Phase
Phase 2
Locations
Israel
Study Type
Interventional
Intervention
Paracetamol
NSAID
D5W
Sponsored by
Shaare Zedek Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Patent Ductus Arteriosus focused on measuring PDA, Paracetamol, Indomethacin, Ibuprofen

Eligibility Criteria

2 Days - 2 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Echocardiographic diagnosis of hemodynamically significant patent ductus arteriosus

Exclusion Criteria:

  • Major congenital anomalies
  • Life-threatening infection
  • Active NEC and/or intestinal perforation
  • Recent (within the previous 24 hours) intraventricular hemorrhage Grade 3-4
  • Urine output <1 ml per kilogram per hour during the preceding 8 hours
  • Serum creatinine concentration of >1.6 mg %
  • Platelet count of <60,000 per cc.

Sites / Locations

  • Shaare Zedek Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Paracetamol

NSAID

Arm Description

Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days

Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr

Outcomes

Primary Outcome Measures

Closure of the Ductus

Secondary Outcome Measures

Absence of peripheral vasoconstriction
Doppler flow velocity in anterior cerebral artery, superior mesenteric artery and renal artery will be measured before and after pharmacologic treatment.
Absence of hepatotoxicity
Liver function will be compared between the two study groups at 1 week following completion of pharmacologic treatment

Full Information

First Posted
February 6, 2011
Last Updated
December 18, 2012
Sponsor
Shaare Zedek Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01291654
Brief Title
Paracetamol and Patent Ductus Arteriosus (PDA)
Official Title
Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Unknown status
Study Start Date
April 2012 (undefined)
Primary Completion Date
December 2014 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shaare Zedek Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators propose that paracetamol will be similarly effective to ibuprofen in treating PDA in the premature neonate, with fewer side effects.
Detailed Description
Preterm neonates with a hemodynamically significant PDA will potentially be candidates for study. After obtaining parental consent, the infants will be prospectively and randomly assigned to one of two groups: 1.po Paracetamol at a dose of 15 mg/kg every 6 hours at x 3 days or Group 2- IV indomethacin - 0.2 mg/kg/dose q 12h for three doses; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).Clinical staff will be blinded as to the study group assignment of the babies and since the group 1 drug is to be given every six hours, all babies will receive a parenteral substance every 6 hours. For Group 2 infants, the intermittent doses will be IV D5W alternating with drug.All infants will fed trophic feeds (20 cc/kg/day) during the treatment for ductal closure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Patent Ductus Arteriosus
Keywords
PDA, Paracetamol, Indomethacin, Ibuprofen

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Paracetamol
Arm Type
Experimental
Arm Description
Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
Arm Title
NSAID
Arm Type
Experimental
Arm Description
Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Intervention Description
po Paracetamol 15 mg/kg every 6 hours x 3 days
Intervention Type
Drug
Intervention Name(s)
NSAID
Intervention Description
IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
Intervention Type
Drug
Intervention Name(s)
D5W
Intervention Description
Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
Primary Outcome Measure Information:
Title
Closure of the Ductus
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Absence of peripheral vasoconstriction
Description
Doppler flow velocity in anterior cerebral artery, superior mesenteric artery and renal artery will be measured before and after pharmacologic treatment.
Time Frame
48 hours
Title
Absence of hepatotoxicity
Description
Liver function will be compared between the two study groups at 1 week following completion of pharmacologic treatment
Time Frame
1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Days
Maximum Age & Unit of Time
2 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Echocardiographic diagnosis of hemodynamically significant patent ductus arteriosus Exclusion Criteria: Major congenital anomalies Life-threatening infection Active NEC and/or intestinal perforation Recent (within the previous 24 hours) intraventricular hemorrhage Grade 3-4 Urine output <1 ml per kilogram per hour during the preceding 8 hours Serum creatinine concentration of >1.6 mg % Platelet count of <60,000 per cc.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cathy Hammerman, MD
Phone
+9722666-6238
Email
cathy@cc.huji.ac.il
First Name & Middle Initial & Last Name or Official Title & Degree
Alona Bin-Nun, MD
Phone
+9722666-6757
Email
alona.binnun@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cathy Hammerman, MD
Organizational Affiliation
Hebrew University Faculty of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shaare Zedek Medical Center
City
Jerusalem
ZIP/Postal Code
91031
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cathy Hammerman, MD
Phone
+9722666-6238
Email
cathy@cc.huji.ac.il
First Name & Middle Initial & Last Name & Degree
Cathy Hammerman, MD

12. IPD Sharing Statement

Learn more about this trial

Paracetamol and Patent Ductus Arteriosus (PDA)

We'll reach out to this number within 24 hrs